Madecassoside 羟基积雪草甙 标准品
分子式 | C48H78O20 |
分子量 | 975.140015 |
储存条件 | Store in dry and dark place. |
纯度 | HPLC : ≥97.5% sum of isomers |
单位 | 瓶 |
货期 | 4周 |
规格 | 10mg |
Madecassoside 羟基积雪草甙 标准品
分子式 | C48H78O20 |
分子量 | 975.140015 |
储存条件 | Store in dry and dark place. |
纯度 | HPLC : ≥97.5% sum of isomers |
单位 | 瓶 |
货期 | 4周 |
规格 | 10mg |
积雪草苷 B
英文名称 | Asiaticoside B |
CAS | 125265-68-1 |
储存条件 | -20℃ |
单位 | 瓶 |
规格 | 20mg |
Asiaticoside 积雪草苷 标准品
CAS | 16830-15-2 |
分子式 | C48H78O19 |
分子量 | 959.140015 |
储存条件 | Store in dry and dark place. |
纯度 | HPLC : ≥99% |
单位 | 瓶 |
货期 | 4周 |
规格 | 10mg |
Madecassoside 羟基积雪草苷 标准品
EC | EINECS 252-076-1 |
MDL | MFCD00017380 |
别名 | 羟基积雪草甙;Asiaticoside A; |
英文名称 | Madecassoside |
CAS | 34540-22-2 |
分子式 | C48H78O20 |
分子量 | 975.12 |
储存条件 | 2-8℃ |
纯度 | HPLC≥98% |
外观(性状) | Off-white Powder |
单位 | 瓶 |
SMILES | O=C(C1(CCC(C)C2C)C2C3=CCC4C(C)(CC(O)C5C4(CC(O)C(O)C5(C)CO)C)C3(C)CC1)OC(C(C(O)C6O)O)OC6COC(C(C(O)C7OC(OC(C)C(O)C8O)C8O)O)OC7CO |
规格 | 20mg |
Asiaticoside 积雪草苷 标准品
EC | EINECS 240-851-7 |
MDL | MFCD06642601 |
别名 | 积雪草单甙;亚细亚皂苷; |
英文名称 | Asiaticoside |
CAS | 16830-15-2 |
分子式 | C48H78O19 |
分子量 | 959.12 |
储存条件 | 2-8℃ |
纯度 | HPLC≥98% |
外观(性状) | Off-white Powder |
单位 | 瓶 |
SMILES | C[C@@H]1CC[C@@]2(C(O[C@@H]3O[C@H](CO[C@H]4[C@H](O)[C@@H](O)[C@H](O[C@@]5([H])[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O5)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@H]3O)=O)[C@@](C6=CC[C@@]([C@](C[C@@H](O)[C@H](O)[C@]7(CO)C)(C)[C@@]7([H])CC8)([H])[C@]8(C)[C@]6(C)CC2)([H])[C@H]1C |
规格 | 20mg |
本品为分析标准品。
Madecassoside;羟基积雪草苷
MDL | MFCD00017380 |
EC | EINECS 252-076-1 |
别名 | 羟基积雪草甙;AsiaticosideA |
英文名称 | Madecassoside |
CAS | 34540-22-2 |
分子式 | C48H78O20 |
分子量 | 975.12 |
纯度 | HPLC≥98% |
单位 | 瓶 |
生物活性 | Madecassoside has potent anti-pulmonary fibrosis (PF) effects.Madecassoside increases the activity of PPAR-γ, which subsequently increases HGF expression in colonic epithelial cells. Madecassoside could protect HUVECs from oxidative injury.[1-2] |
In Vitro | Madecassoside (10, 30, 100 μmol/L) could reverse morphological changes, elevate cell viability, increase glutathione levels, and decrease lactate dehydrogenase andmalondialdehyde levels caused by H2O2 in a concentration-dependent manner. It attenuates apoptosis, preventing the activation of caspase-3 and the loss of mitochondria membrane potential, as well as the phosphorylation of p38 mitogen activated protein kinase (MAPK) in HUVECs. Hence, Madecassoside could protect HUVECs against lipid peroxidation and apoptosis caused by H2O2[1]. |
In Vivo | The pharmacokinetic study of madecassoside in rats indicates that the maximum plasma concentration is 303.75 ± 28.53 ng/mL after single oral administration (100 mg/kg). Madecassoside, administered orally for 20 days at doses of 6, 12, and 24 mg/kg, effectively facilitates burn wound healing in mice. It could reduce the burn wound area, leading to a better healing pattern with almost complete wound closure in mice[1]. Madecassoside has potent anti-pulmonary fibrosis (PF) effects when administered p.o., despite having extremely low oral bioavailability. The potent anti-PF effects induced by p.o. madecassoside in mice are not mediated by its metabolites or itself after absorption into blood. i.p. madecassoside has no anti-PF effect. Madecassoside increases the activity of PPAR-γ, which subsequently increases HGF expression in colonic epithelial cells. HGF then enters into the circulation and lung tissue to exert an anti-PF effect[2]. |
SMILES | O=C(C1(CCC(C)C2C)C2C3=CCC4C(C)(CC(O)C5C4(CC(O)C(O)C5(C)CO)C)C3(C)CC1)OC(C(C(O)C6O)O)OC6COC(C(C(O)C7OC(OC(C)C(O)C8O)C8O)O)OC7CO |
靶点 | Others |
动物实验 | HUVECs are harvested using 0.25% trypsin solution and inoculated in 96-well plates at a density of 1 × 104 cells/well. Cells are treated with H2O2 (500 μmol/L) and/or a variety of concentrations of madecassoside (10, 30, 100 μmol/L). The culture plate is then placed in 5% (v/v) CO2 at 37?C for 8 h. At the end of incubation, 20 μL of MTT (5 mg/mL) is added to each well and the cells are incubated for another 4 h at 37?C with 5% CO2. The supernatants are then discarded, and 200 μL of DMSO is added to each well. The absorbance is read at 540 nm and cell viability is expressed as percentage of untreated cells.[1] |
细胞实验 | Animal Models: Female ICR mice, 6-8 weeks-old and weighing 22-26 g; Dosages: 40 mg/kg; Administration: p.o. or i.p.[2] |
数据来源文献 | [1] Bian D, et al. J Biochem Mol Toxicol. 2012, 26(10):399-406. [2] Xia Y, et al. Br J Pharmacol. 2016, 173(7):1219-35. |
规格 | 5mg 10mg 20mg |
Madecassoside是一个五环三萜。
积雪草苷B 标准品
有效期 | 2年 |
MDL | MFCD32197362 |
英文名称 | Asiaticoside B |
CAS | 125265-68-1 |
分子式 | C48H78O20 |
分子量 | 975.12 |
储存条件 | 2-8℃ |
纯度 | HPLC≥98% |
外观(性状) | powder |
单位 | 瓶 |
SMILES | OC[C@H]([C@@H](O[C@@]1([H])[C@@H]([C@@H]([C@@H](O)[C@H](C)O1)O)O)[C@H](O)[C@H]2O)O[C@H]2OC[C@H]([C@@H](O)[C@H](O)[C@H]3O)O[C@H]3OC([C@]45[C@](CC(C)(C)CC5)([H])C6=CC[C@@]([C@@]7([C@@]([C@@](C)([C@@H](O)[C@H](O)C7)CO)([H])[C@H](O)C8)C)([H])[C@]8(C)[C@]6(C)CC4)=O |
规格 | 20mg |
Asiaticoside;积雪草苷
MDL | MFCD06642601 |
EC | EINECS 240-851-7 |
别名 | 积雪草单甙;亚细亚皂苷 |
英文名称 | Asiaticoside |
CAS | 16830-15-2 |
分子式 | C48H78O19 |
分子量 | 959.12 |
纯度 | HPLC≥98% |
生物活性 | Asiaticoside 是从积雪草中分到的三萜皂苷化合物,在瘢痕疙瘩成纤维细胞中,通过活化 Smad7,抑制 TGF-βRI 和 TGF-βRII,抑制 TGF-β/Smad 信号通路;Asiaticoside 具有抗氧化、抗炎、抗溃疡等功效。[1-3] |
In Vitro | 积雪草苷(0,100,250和500mg/L)剂量依赖性地抑制瘢痕疙瘩成纤维细胞增殖。积雪草苷(100,250和500 mg/L)可降低胶原蛋白和mRNA的表达,降低TGF-bRI,TGF-βRII蛋白和mRNA的表达,增加Smad7的表达,但不影响Smad2,Smad3瘢痕疙瘩成纤维细胞中有Smad4,磷酸化Smad2和磷酸化Smad3 [1]。积雪草苷(12.5和50,以及25和50μg/ mL)可防止内皮细胞缺氧诱导的细胞活力和NO产生的抑制。积雪草苷(50μg/ mL)也可以保护内皮细胞免受低氧诱导的细胞凋亡,并在缺氧暴露的HPAECs中上调和磷酸化AKT/eNOS [2]。 |
In Vivo | 积雪草苷(每日50mg/kg)可阻断肺动脉高压大鼠缺氧性肺动脉高压(PH),心血管重塑和内皮细胞损伤[2]。积雪草苷(5,15或45 mg/kg,po)改善学习和记忆缺陷,保护海马免受损伤,减少海马中的Aβ沉积,并改善用Aβ寡聚体处理的大鼠中受损的亚细胞结构[3]。 |
SMILES | C[C@@H]1CC[C@@]2(C(O[C@@H]3O[C@H](CO[C@H]4[C@H](O)[C@@H](O)[C@H](O[C@@]5([H])[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O5)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@H]3O)=O)[C@@](C6=CC[C@@]([C@](C[C@@H](O)[C@H](O)[C@]7(CO)C)(C)[C@@]7([H])CC8)([H])[C@]8(C)[C@]6(C)CC2)([H])[C@H]1C |
靶点 | TGF-beta/Smad |
动物实验 | 大鼠[3] Sprague-Dawley大鼠用于建立阿尔茨海默氏病(AD)模型。积雪草苷以5,15或45mg/kg体重每天口服给药7天。在手术后7天通过MWM测试评估大鼠的学习和记忆功能。游泳池(直径180厘米)保持在22-24°C,并分成四个相同大小的象限。隐藏平台放置在一个象限的中心。这四个象限的每个基点都是随机选择作为起始位置。在预测试日,允许大鼠自由游泳120秒。在测试期间(第1-4天),每只大鼠每天进行8次试验。当将大鼠放入池中时,试验开始,并且当大鼠找到平台时结束。记录逃避延迟。如果大鼠在120秒内未能找到平台,则终止试验并将逃避潜伏期记录为120秒,并将大鼠引导至平台。在第5天,通过视频记录系统记录游泳路径,并且通过水迷宫软件分析数字图像。另外,进行探针测试,其中移除平台,并允许大鼠在池中自由游动120秒。记录目标象限中的游泳时间[3]。 |
细胞实验 | 将细胞以2-9×10 4个细胞/ mL的密度接种到24孔板中以获得细胞活力,将60-mm接种板用于RNA并在含有10%FBS(DMEM/10%FBS)的DMEM中进行蛋白质分析。 24小时后,除去培养基,将细胞置于无血清DMEM中。 48小时后,将不同浓度的积雪草苷在DMEM/10%FBS中同时加入细胞中。对照细胞在DMEM/10%FBS中生长,不添加积雪草苷。在不同时间点,收获成纤维细胞用于分析[1]。 |
数据来源文献 | [1]. Tang B, et al. Asiaticoside suppresses collagen expression and TGF-β/Smad signaling through inducing Smad7 and inhibiting TGF-βRI and TGF-βRII in keloid fibroblasts. h Dermatol Res. 2011 Oct;303(8):563-72. [2]. Wang X, et al. Effect of asiaticoside on endothelial cells in hypoxia‑induced pulmonary hypertension. Mol Med Rep. 2018 Feb;17(2):2893-2900. [3]. Zhang Z, et al. Asiaticoside ameliorates β-amyloid-induced learning and memory deficits in rats by inhibiting mitochondrial apoptosis and reducing inflammatory factors. Exp Ther Med. 2017 Feb;13(2):413-420 |
规格 | 5mg 10mg 10mM*1mL in DMSO |
是一种三萜皂苷化合物。
积雪草苷 标准品
英文名称 | Asiaticoside |
CAS | 16830-15-2 |
分子式 | C48H78O19 |
分子量 | 959.12 |
储存条件 | 2-8℃ |
规格 | 20mg |
羟基积雪草苷 标准品
英文名称 | Madecassoside |
CAS | 34540-22-2 |
分子式 | C48H78O20 |
分子量 | 975.12 |
储存条件 | 2-8℃ |
规格 | 20mg |
熔点:220-223